nucleolar protein 4 likeGenealiases: C20orf112 · C20orf113
Q-omics provides the consensus-scored NOL4L profile across patient tissues and cancer cell-line models. NOL4L expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NOL4L is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NOL4L RNA expression shows 21,222 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where NOL4L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOL4L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOL4L survival associations across molecular data types. NOL4L RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOL4L RNA expression–survival associations across cancer types. High NOL4L expression shows unfavorable associations in ACC, LUSC, KIRP and UCEC, but favorable associations in BLCA and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NOL4L RNA expression.
This table summarizes NOL4L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NOL4L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOL4L shows higher tumor expression in HNSC, THCA, LIHC, STAD, BRCA and CHOL. The HNSC box plot shows higher NOL4L RNA expression in tumor versus normal tissue (log2 FC = +1.323, t-test p < 0.001).
This table shows molecular features associated with NOL4L in patient tissues and cancer cell lines. In patient samples, NOL4L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOL4L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
